Prosecution Insights
Last updated: November 20, 2026
Application No. 18/845,317

SUBSTITUTED IMIDAZO[1,5-A]PYRIDINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME

Non-Final OA §102
Filed
Sep 09, 2024
Priority
Mar 10, 2022 — provisional 63/318,481 +1 more
Examiner
INAM, SAHAR
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Rutgers, The State University of New Jersey
OA Round
1 (Non-Final)
100%
Grant Probability
Favorable
1-2
OA Rounds
6m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 100% — above average
100%
Career Allowance Rate
2 granted / 2 resolved
+40.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
24 currently pending
Career history
27
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
40.0%
+0.0% vs TC avg
§102
21.5%
-18.5% vs TC avg
§112
32.3%
-7.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 2 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicants’ election without traverse of Group I (i.e., claims 1-2, 5, 7, 10, 12, 14, 19 and 21) in the reply filed on 09/09/2026 is acknowledged. Applicants’ amendment of claims 2, 5, 7, 10, 12, 14, 19 and 21 is acknowledged. Furthermore, applicant’s election of the following species “Compound 19” for Group I PNG media_image1.png 172 200 media_image1.png Greyscale without traverse is acknowledged. Since the applicant elected group I (i.e., claims 1-2, 5, 7, 10, 12, 14, 19 and 21), therefore, based on that election, claims 22-23, 26, 28, 31, 33, 35, 40, 46-47 and 65 are withdrawn as being drawn to a non-elected group. Claims 1-2, 5, 7, 10, 12, 14, 19, and 21 are under consideration in this office action and will be examined on the merits. Status of Claims Claims 1-66 were originally pending. The preliminary amendment filed 09/09/2024 amended claims 2, 5, 7, 10, 12, 14, 19, 21, 23, 26, 28, 31, 33, 35, 40, 46-47, and 65; canceled claims 3-4, 6, 8-9, 11, 13, 15-18, 20, 24-25, 27, 29-30, 32, 34, 36-39, 41-45, 48-64, and 66. There are no new claims. Claims 1-2, 5, 7, 10, 12, 14, 19 and 21 are under consideration in the instant office action. Information Disclosure Statement The information disclosure statement (IDS) submitted on 09/09/2024 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-2, 5, 7, 10, 12, 14, 19, and 21 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by US PG-PUB 2014/0248646 A1 to Hutt et al. (“IMIDAZO1.5-APYRIDINIUM ION FLUOROPHORES, AND METHODS OF MAKING AND USING THE SAME”, published September 4, 2014) herein referred to as Hutt. Regarding claims 1-2, 5, 7, 10, 12, 14, 19 and 21, Hutt teaches Imidazo[1,5-a] pyridinium ion core having the formula similar to the compounds of Formula I. PNG media_image2.png 78 658 media_image2.png Greyscale PNG media_image3.png 234 470 media_image3.png Greyscale Hutt discloses a compound comprising azo[1.5-a]pyridinium core of formula I (Compound 21, or 5-(4-(dimethylamino)phenyl)-2-(4-methoxyphenyl)-2H-imidazo[1.5-ajpyridin-4-ur tetraphenylborate, as shown in schemes 3 and 4 on page 26 of the instant application, the compound of the formula I shown as the compound 3-1 in schemes 3 and 4, can exist in two tautomeric forms having positive charge either at the N2 nitrogen atom or N4 nitrogen atom of the imidazo[1.5-a]pyridinium core, the numbering of the core is in accordance with the system shown in paragraph [0206]; paragraphs [0204], [0206]), wherein T1 is CR1a, R1a is H (the hydrogen is attached to the C6 carbon atom of the imidazo[1.5-a]pyridinium core, the numbering of the core is in accordance with the system shown in paragraph [0206]; paragraphs [0204], [0206]); T2 is CR2a, R2a is H (the hydrogen is attached to the C7 carbon atom of the imidazo[1.5-a]pyridinium core; paragraphs [0204], [0206]); T3 is CR3a, R3a is H (the hydrogen is attached to the C8 carbon atom of the imidazo[1.5-a]pyridinium core; paragraphs [0204], [0206]); R2 is H (the hydrogen is attached to the c1 carbon atom of the imidazo[1.5-a]pyridinium core; paragraphs [0204], [0206]); R3 is substituted C6 aryl, wherein substituent in R3 is C1 alkoxy (4-methoxyphenyl moiety is attached to the N2 nitrogen of the imidazo[1.5-a]pyridinium core; paragraphs [0204], [0206]); R4 is phenyl substituted with N(RA)(RB), RA and RB are H (the 4-(dimethylamino)phenyl moiety is attached to the C5 carbon of the imidazo[1.5-a]pyridinium core; paragraphs [0204], [0206]); X is a counter anion (the tetraphenylborate counter ion as in the compound; paragraphs [0204], [0206]); wherein if T1 is CH, T2 is CH, T3, is CH, and R2 is H, then each of the following apply: If R4 is 2,4,6-triisopropylphenyl, then R3 is not 2,6-diisopropylphenyl, 2,4,6-trimethylphenyl, 2-methylphenyl, or 2,6-diethyl-4-methylphenyl (R4 is 4-(dimethylamino)phenyl, not 2,4,6-trilsopropylphenyl; paragraphs [0204], [0206]); b) If R4 is 2,4,6-trimethylphenyl, then R3 is not 2,4,6-trimethylphenyl, 2,6-diisopropylphenyl, adamantly, 4-(2-(2-methoxyethoxy)ethoxy)-2,6-dimethylphenyi, or (2-(2-methoxyethoxy)ethoxy)phenyl (R4 is 4-(dimethylamino)phenyl, not 2,4,6-trimethylphenyl; paragraphs [0204], [0206]); c) If R4 is 2-methylphenyl, then R3 is not 2,6-diisopropylphenyl (R4 is 4-(dimethylamino)phenyl, not 2-methylphenyl; paragraphs [0204], [0206]); d) If R4 is 4-tert-butyl-2-pyridyl, then R3 is not 2,6-diisopropylphenyl (R4 is 4-(dimethylamino)phenyl, not paragraphs [0204], [0206]); and e) If R4 is 5-tetrahydroisoquinolinyl, then R3 is not 2,6-dilsopropylphenyl (R4 is 4-(dimethylamino)phenyl, not 5-tetrahydroisoquinolinyl; paragraphs [0204], [0206]). The scope of Hutt’s compounds overlaps with Formula I of the instant claims. Based on the foregoing reasons, the instant claims are deemed anticipated over the cited art. Conclusion Claims 1-2, 5, 7, 10, 12, 14, 19 and 21 are rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAHAR INAM whose telephone number is (571)272-0821. The examiner can normally be reached 7:30 am-5:00 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James H Alstrum-Acevedo can be reached at (571) 272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SAHAR INAM/ Examiner, Art Unit 1622 /JAMES H ALSTRUM-ACEVEDO/ Supervisory Patent Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Sep 09, 2024
Application Filed
Oct 22, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797349
USE OF METHYLAMINOCOLCHICINE AND SALT THEREOF
3y 1m to grant Granted Nov 17, 2026
Patent 12780813
HSD17B13 INHIBITORS AND/OR DEGRADERS
3y 0m to grant Granted Nov 03, 2026
Patent 12760000
PYRIDAZINE DERIVATIVES AS MODULATORS OF NLRP3 INFLAMMASOME AND RELATED METHODS
2y 3m to grant Granted Oct 13, 2026
Patent 12753162
METHOD FOR PRODUCING 2-HETEROARYLPYRIDINE COMPOUND
2y 6m to grant Granted Oct 06, 2026
Patent 12734164
PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY
2y 11m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
100%
Grant Probability
99%
With Interview (+0.0%)
2y 8m (~6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 2 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month